RESUMEN
Objective To investigate the distribution of hepatitis B virus(HBV) genotypes ,drug resistance situation of hepatitis B patients and the relation between HBV genotype with drug resistance and mutation sites .Methods Three hundred serum samples of HBV patients were collected and HBV‐DNA was extracted by adopting the centrifugal column method .The HBV genotype and drug resistant mutant were detected by using PCR‐reverse dot blot hybridization method .Results In 300 cases of HBV‐DNA posi‐tive ,genotye B ,C ,B/C and other undetected genotypes were detected out ,but genotype D was not detected out ,in which genotype C was predominant ,accounting for 81 .8% ;in the HBV patients ,the resistant drugs were dominated by‐lamivudine and telbivudine , accounting for 43 .6% ;the HBV drug resistant mutation genotypes were mainly rt204I(24 .35% ) ,rt204V (17 .39% ) and rt180M (17 .39% );the drug resistance mutation rates of genotype B and C were 30 .77% and 42 .42% respectively ;the difference was sta‐tistically significant(P<0 .05) .Conclusion HBV genotype C in Dongying area is more than genotype B ,genotype C is prone to produce drug resistance ,rt204I ,rt204V and rt180M gene mutations are common ,lamivudine and telbivudine combined resistance is common ,the suitable treatment scheme should be selected according to genotyping and drug resistance mutations results .
RESUMEN
BACKGROUND: Despite significant progress in vaccine and therapeutic regimen, hepatitis B virus (HBV) infection remains one of the major diseases. Long-term use of lamivudine can induce the emergence of drug resistance. TRUGENE(TM) HBV Genotyping (Visible Genetics Inc., Ga, USA) is an assay that reports the viral genotype and mutations likely to confer resistance to antiviral therapy. In this study, we analyzed HBV genotype and mutations and correlated them with the histologic grade and stage of the liver disease to provide the useful information about the therapy of chronic liver disease. METHODS: HBV DNA was isolated from 86 patients with HBV-associated chronic liver diseases and analyzed by TRUGENE(TM) HBV Genotyping. Histologic grade and stage were correlated with RESULTS: HBV genotypes of 86 patients were all C (100%). Mutations associated with lamivudine resistance were detected in 10 patients (11.6%) and M204I (YIDD) mutant was the most common. Unknown mutation such as L180F was also detected. Statistical analysis showed that the number of coding changes at HBsAg region was significantly correlated with the lobular activity (P=0.01). CONCLUSIONS: All patients were genotype C and lamivudine resistant mutations were detected in 11.6%. L180F mutation, not known previously, was detected in one case. Number of coding changes at HBsAg region was significantly correlated with the lobular activity. It was considered that follow-up studies about the clinical significance of coding changes in HBsAg are needed, and that a further study such as in vitro transfection is necessary to confirm the possibility of a novel mutation of L180F.